LumosVar — a name inspired by Harry Potter — could help physicians provide genomic-based treatments for their patients
By conjuring the spell “Lumos!” wizards in the mythical world of Harry Potter could light up the tip of their magic wands and illuminate their surroundings. So, too, does LumosVar, a computer program developed by the Translational Genomics Research Institute (TGen), “light up” cancer-causing genetic Var-ients, or mutations, illuminating how physicians might best treat their patients.
A study published today in the scientific journal Frontiers in Oncology describes how researchers at TGen, an affiliate of City of Hope, developed LumosVar to create a tool that can accurately identify cancer-causing mutations from patient tumor samples.
In the case of archived samples from patients for which treatment outcome results are known, these represent a treasure trove of information that could accelerate research by investigators and physicians in predicting responses of future patients to particular treatments.
“There are many open questions in precision oncology that can only be answered by collecting large amounts of patient genomic data linked to treatment response and clinical outcomes,” said Dr. Rebecca Halperin, a Research Assistant Professor in TGen’s Quantitative Medicine and Systems Biology Program.
“The approach we outline in this study should enable researchers to use archival samples more effectively. Accurately calling, or identifying, somatic variants — those DNA changes specific to a patient’s cancer — are the first step in any analysis,” said Dr. Halperin, the study’s lead author.
However, archived tumor samples are frequently not accompanied by the patients’ normal — or germline — genetic information, making it difficult to distinguish the patient’s normal DNA variants to their mutated and cancerous DNA changes.
LumosVar is a precise enough tool that it not only can detect the cancerous DNA from a patient sample, but it also can differentiate the adjacent normal DNA that may surround the tumor in the sample. Comparing the patient’s normal DNA from a suspected cancer-causing mutation is critical to eliminating benign, non-cancerous variants in the sample — “false positives” — and ensuring that the tissue sample analysis is as accurate as possible.
A high level of accuracy is needed for physicians to use this information in precision medicine, determining what treatment each individual patient should receive.
“The sequencing of DNA from tissue adjacent to the tumor could help identify somatic, or cancer-causing, mutations when another source of normal tissue is not available,” said Dr. Sara Byron, Research Assistant Professor in TGen’s Integrated Cancer Genomics Division, and also the study’s senior author.
Learn more: AS IF BY MAGIC: TGEN DEVELOPS PROGRAM THAT LIGHTS UP CANCER-CAUSING MUTATIONS
The Latest on: Genomic-based treatments
[google_news title=”” keyword=”genomic-based treatments” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Genomic-based treatments
- Examining the impact of gene-based breeding on agriculture and medicineon April 25, 2024 at 10:22 am
A research team has demonstrated that gene-based breeding (GBB) offers a transformative approach to advancing plant and animal breeding, showing remarkable predictability, speed, and ...
- NIH Reports a Gene-Based Therapy Restores Cellular Development and Function in Brain Cells from People with Timothy Syndromeon April 25, 2024 at 8:00 am
NIH Reports a Gene-Based Therapy Restores Cellular Development and Function in Brain Cells from People with Timothy Syndrome ...
- BioAro Announces a Medical and Computing Breakthrough by Launching the 'World's Fastest' Real-Time Genomic Software 'PanOmiQ'on April 25, 2024 at 6:50 am
BioAro, a pioneer in genomic research and technology, is set to officially launch PanOmiQ, a revolutionary software that will redefine the landscape of genomic analysis globally by providing real-time ...
- Experts call for global genetic warning system to combat the next pandemic and antimicrobial resistanceon April 25, 2024 at 2:00 am
The COVID-19 pandemic turned the world upside down. In fighting it, one of our most important weapons was genomic surveillance, based on whole genome sequencing, which collects all the genetic data of ...
- Producing Commercial-Scale Plant-Based Protein with Genetic Engineeringon April 24, 2024 at 1:00 pm
And there are benefits of plant cell expression systems, notably their impact on the cost of goods sold (COGS).
- Genetics predict type 2 diabetes risk and disparities in childhood cancer survivorson April 24, 2024 at 11:50 am
Survivors of childhood cancer are at increased risk for cardiovascular disease, for which a risk factor is their greater prevalence of type 2 diabetes, with a disproportionate impact on those of ...
- Giant virus discovered in wastewater treatment plant infects deadly parasiteon April 24, 2024 at 8:37 am
The single-celled organism Naegleria fowleri ranks among the deadliest human parasites. Researchers around Matthias Horn and Patrick Arthofer from the Center for Microbiology and Environmental Systems ...
- Cutting-edge RM6 Million Laboratory Opens at UMMC to Advance Cancer Treatmenton April 23, 2024 at 11:27 pm
Cancer patients can approach UMMC for enquiries on Auxi Therapeutics GMP CAR-T & CGT Laboratory. Blood cancer patients may contact Consultant Clinical Haematologist Prof Dr Bee Ping Chong, and ...
- Targeted Therapy, Treatment Disparity Featured at Cancer Meetingon April 23, 2024 at 12:42 pm
Leading cancer researchers from UC San Francisco presented talks about advances in targeted therapy, cancer genomics, eliminating treatment disparities and other cancer research topics at this year’s ...
- The Largest Whole-genome Sequencing Study in Canceron April 17, 2024 at 7:46 am
Comprehensive genome sequencing of 13,880 tumors revealed somatic and germline mutations that could influence patient treatment and prognosis.
via Bing News